Domov › Kronična limfocitna levkemija › Kalifornija

Klinične študije za Kronična limfocitna levkemija v Kalifornija

33 študij za Kronična limfocitna levkemija išče udeležence na lokacijah v Kalifornija.

Mesta v Kalifornija

Uradno besedilo študije (angleško)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Kaiser Permanente-Anaheim, Anaheim
Kaiser Permanente-Baldwin Park, Baldwin Park
Kaiser Permanente-Bellflower, Bellflower
in še 12

Vključevanje udeležencevFaza 3

Starost 65 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
PCR Oncology, Arroyo Grande
AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
in še 20

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci

Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, La Jolla

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06542250

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Kaiser Permanente-Anaheim, Anaheim
Kaiser Permanente-Baldwin Park, Baldwin Park
Kaiser Permanente-Bellflower, Bellflower
in še 28

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

GC2202 Study Site 115, Huntington Park

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Uci Health Laguna Hills, Laguna Hills
Chao Family Comprehensive Cancer Center, Orange
Stanford Cancer Institute, Palo Alto
in še 1

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Stanford Medicine, Palo Alto
UCLA Santa Monica Cancer Care, Santa Monica

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

City of Hope National Medical Center, Duarte
Chao Family Comprehensive Cancer Center, Orange
Stanford Cancer Institute, Palo Alto

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07277231

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

UCLA Department of Medicine Hematologyoncology, Los Angeles
Scripps Prebys Cancer Center, San Diego
Pih Health Whittier Hospital, Whittier

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Kaiser Permanente Southern California, Irvine
University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Cancer and Blood Specialty Clinic, Los Alamitos
in še 8

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06973187

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Moores Cancer Center ( Site 0003), La Jolla
Care Access - South Pasadena ( Site 0070), Pasadena

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06136559

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

City of Hope, Duarte
Cedars-Sinai Medical Center, Los Angeles
Scripps Health, San Diego

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

City of Hope Comprehensive Cancer Center, Duarte
City of Hope at Irvine Lennar, Irvine
University of California Davis Comprehensive Cancer Center, Sacramento

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07061951

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

City of Hope National Medical Center, Duarte

Vključevanje udeležencevFaza 1/2

Starost 12 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT04588922

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Pacific Cancer Medical Center, Inc, Anaheim
TOI Clinical Research, Cerritos
Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT05254743

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

City of Hope, Duarte

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT06528301

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Vključevanje udeležencevFaza 1/2

Starost 13–90 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06533579

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

City of Hope Medical Center, Duarte

Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci

Starost 18–75 · Vsi spoli · Posodobljeno 28. jul. 2026 · NCT07020533

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 2. jul. 2026 · NCT05131022

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT04545762

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

City of Hope National Medical Center, Duarte
City of Hope National Medical Center, Irvine
Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto
in še 1

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 19. maj 2026 · NCT06588478

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 20. apr. 2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
in še 1

Vključevanje udeležencevFaza 1/2

Starost 12–95 · Vsi spoli · Posodobljeno 15. apr. 2026 · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

UCSF FRESNO/Community Cancer Institute /ID# 270874, Clovis
Valkyrie Clinical Trials /ID# 268151, Los Angeles

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 9. apr. 2026 · NCT06428019

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Stanford Cancer Institute Palo Alto, Palo Alto

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. mar. 2026 · NCT05388006

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 20. mar. 2026 · NCT04830137

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
City of Hope at Long Beach Elm, Long Beach

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 13. mar. 2026 · NCT07218510

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center, Duarte

Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci

Starost 18–75 · Vsi spoli · Posodobljeno 10. mar. 2026 · NCT06059391

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Moores Cancer Center at UC San Diego /ID# 230157, La Jolla

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 9. feb. 2026 · NCT04895436

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 10. dec. 2025 · NCT05602363

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

San Francisco VA Medical Center, San Francisco, CA, San Francisco

Vključevanje udeležencevFaza 2

Starost 18–80 · Vsi spoli · Posodobljeno 14. okt. 2025 · NCT06520098

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.